JTE 052

Drug Profile

JTE 052

Alternative Names: JTE-052; JTE-052A

Latest Information Update: 07 Nov 2016

Price : $50

At a glance

  • Originator Japan Tobacco
  • Class Antiallergics
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Autoimmune disorders; Hypersensitivity; Inflammation

Most Recent Events

  • 28 Oct 2016 Japan Tobacco and Torii Pharmaceutical agree to co-develop and commercialise JTE 052 in Japan for Skin disorders
  • 25 May 2016 Japan Tobacco completes a phase-II trial in Atopic dermatitis in Japan (JapicCTI-152887)
  • 04 Aug 2015 Phase-II clinical trials in Autoimmune disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top